| Dr Shelly L Hearn, MD | |
|
1729 Burrstone Rd, New Hartford, NY 13413-1001 | |
| (315) 798-1702 | |
| (315) 798-1707 |
| Full Name | Dr Shelly L Hearn |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 1729 Burrstone Rd, New Hartford, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134113343 | NPI | - | NPPES |
| 02565391 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 233294 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Slocum Dickson Medical Group Pllc | 5799778510 | 111 |
News Archive
Many neurological disorders, such as Parkinson's disease and Alzheimer's disease, are marked by impaired motor skills. In addition, growing evidence suggests there's a link between some neurodegenerative diseases and body weight. A recent NIH study, for example, found that adults who are obese or overweight at midlife may be at risk for earlier onset of Alzheimer's disease.
arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.
AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.
Females who participate in competitive sport during adolescence have better fitness at midlife than do females with no competitive sport background in adolescence, reveals a study conducted at the University of Jyväskylä.
TomoTherapy Incorporated announced today that the Institute Curie Hospital in France has purchased a second TomoTherapy® radiation therapy system, to support the increasing demand for intensity-modulated radiation therapy (IMRT). The Institute Curie Hospital has been treating cancer patients with TomoTherapy technology since March 2007, when it became the first hospital in France to adopt the technology.
› Verified 4 days ago
| Entity Name | Slocum Dickson Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285625996 PECOS PAC ID: 5799778510 Enrollment ID: O20040407000427 |
News Archive
Many neurological disorders, such as Parkinson's disease and Alzheimer's disease, are marked by impaired motor skills. In addition, growing evidence suggests there's a link between some neurodegenerative diseases and body weight. A recent NIH study, for example, found that adults who are obese or overweight at midlife may be at risk for earlier onset of Alzheimer's disease.
arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.
AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.
Females who participate in competitive sport during adolescence have better fitness at midlife than do females with no competitive sport background in adolescence, reveals a study conducted at the University of Jyväskylä.
TomoTherapy Incorporated announced today that the Institute Curie Hospital in France has purchased a second TomoTherapy® radiation therapy system, to support the increasing demand for intensity-modulated radiation therapy (IMRT). The Institute Curie Hospital has been treating cancer patients with TomoTherapy technology since March 2007, when it became the first hospital in France to adopt the technology.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shelly L Hearn, MD 1729 Burrstone Rd, New Hartford, NY 13413-1001 Ph: (315) 798-1702 | Dr Shelly L Hearn, MD 1729 Burrstone Rd, New Hartford, NY 13413-1001 Ph: (315) 798-1702 |
News Archive
Many neurological disorders, such as Parkinson's disease and Alzheimer's disease, are marked by impaired motor skills. In addition, growing evidence suggests there's a link between some neurodegenerative diseases and body weight. A recent NIH study, for example, found that adults who are obese or overweight at midlife may be at risk for earlier onset of Alzheimer's disease.
arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.
AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.
Females who participate in competitive sport during adolescence have better fitness at midlife than do females with no competitive sport background in adolescence, reveals a study conducted at the University of Jyväskylä.
TomoTherapy Incorporated announced today that the Institute Curie Hospital in France has purchased a second TomoTherapy® radiation therapy system, to support the increasing demand for intensity-modulated radiation therapy (IMRT). The Institute Curie Hospital has been treating cancer patients with TomoTherapy technology since March 2007, when it became the first hospital in France to adopt the technology.
› Verified 4 days ago
David Petrie, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3946 Oneida St., New Hartford, NY 13413 Phone: 315-624-8300 Fax: 315-624-5152 | |
Arul Kannan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95 Genesee St, New Hartford, NY 13413 Phone: 315-724-7366 Fax: 315-724-0293 | |
Jane Samson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 Genesee St, New Hartford, NY 13413 Phone: 315-797-2314 Fax: 315-797-0850 | |
Dr. Joseph I Raj, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1729 Burrstone Rd, New Hartford, NY 13413 Phone: 315-798-1700 Fax: 315-798-1707 | |
Dr. John S Robertson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3946 Oneida St, New Hartford, NY 13413 Phone: 315-624-8300 Fax: 315-624-8310 | |
William Hall, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3946 Oneida St., New Hartford, NY 13413 Phone: 315-624-8300 Fax: 315-624-5152 |